Research Updates

Research Briefings Built to Convert Newsletter Traffic

Newsletter companion articles that turn peptide research updates into crawlable SEO pages, product pathways, and high-intent catalog CTAs.

Newsletter linkedSEO crawlableProduct CTA ready

Shop Research Peptides Read Latest Update

Research Use Only

COA-Focused Context

Educational Updates

Research Updates Built From Newsletter Topics

View catalog →

Peptide Research ReportMay 5, 20268 min read

The Great Compounding Reversal, CagriSema's Report Card, and the May 2026 Cardiometabolic Pipeline

The February 2026 HHS reversal restores Category 1 access for BPC-157, Thymosin Alpha-1, CJC-1295, and MOTS-c. Plus the latest data on CagriSema, Survodutide, MariTide, Mazdutide, and the emerging Picobody and Graspetide classes.

14–19

Peptides being restored to Category 1 status by HHS

23%

CagriSema 84-week weight loss in REDEFINE-4 Phase III

18.6%

Mazdutide placebo-adjusted weight reduction in MED Journal data

Read Article Shop Research Peptides

Peptide Research ReportApril 29, 20267 min read

Retatrutide, Amylin Analogs, and the Rise of Muscle-Preserving Research

A research update covering Retatrutide Phase 3 data, emerging amylin analogs, and myostatin inhibitors for lean-mass preservation in the GLP-1 era.

16.8%

Retatrutide weight-loss signal in Phase 3 topline data

10.7%

Amylin analog weight-loss signal with strong tolerability

92.2%

Fat-mass share of weight loss in Bimagrumab combination data

Read Article Shop Research Peptides